Tag: Patient savings

According to data from GoodRx, some Medicare prescription drug plans place brand-name bromfenac on Tier 3 or 4, significantly impacting out-of-pocket costs. The specific insurance tier for **bromfenac** varies widely depending on your individual plan and whether you are prescribed the generic or a brand-name version.

In the United States, the brand-name version of the oral diabetes drug acarbose, known as Precose, was discontinued, leaving only the generic version available for patients. This means that the answer to 'Is there a generic for acarbose?' is yes, and it is the primary option on the market.

According to recent analyses, some biosimilar versions of Hyrimoz can have a list price that is over 80% lower than Humira's list price. This makes answering the question, is Hyrimoz cheaper than Humira, a complex matter that depends heavily on the specific version, insurance coverage, and discount programs available to the patient.

While specific retail prices for Megabrom eye drops vary significantly depending on the pharmacy and location, the average retail price for its active ingredient, generic bromfenac, can range widely in the United States, often exceeding $300 for a bottle without discounts. Megabrom is primarily an international brand name, so it is more helpful to explore the cost of its equivalent, bromfenac, within the U.S. market.

Without insurance, the list price for a one-month supply of Mounjaro is around $1,080, while Ozempic's list price is slightly lower at approximately $998. The answer to which is more expensive, Ozempic or Mounjaro, is not always simple, as the final out-of-pocket cost is heavily influenced by insurance coverage, savings cards, and pharmacy choice.